Fig 3.

SINE molecules work synergistically with doxorubicin, bortezomib, and carfilzomib in H929 cells. SINE compound KPT185 was serially diluted, added to the wells containing H929 MM cells grown at plateau densities (2 x 10⁶/mL), and incubated overnight at 37°C and 5% CO₂. Doxorubicin (A), bortezomib (B), carfilzomib (C), lenalidomide (D), dexamethasone (E), and melphalan (F) were serially diluted and added the following day, and the plates were incubated an additional 24 hours. Samples were assayed for cell viability (CellTiter-Blue reagent) in replicates of 2-4 (see Table 2). Percent viability versus drug concentration was plotted. SINE compounds were found to be synergistic with doxorubicin, bortezomib, and carfilzomib, additive with melphalan, and non-synergistic/antagonistic for lenalidomide and dexamethasone in H929 cells.